By Christiana Sciaudone
Investing.com — Shares of biotech firm Inovio Pharmaceuticals (NASDAQ:INO) Inc. closed up 31% on Thursday, even after Citron Research said shares would tumble.
Inovio said Tuesday it was receiving $71 million from the U.S. Department of Defense to manufacture a device used to administer an Inovio vaccine against Covid-19 that has not been approved.
Citron, calling Inovio a favorite stock of Robinhood investors, said the shares are likely to drop by 50%, to $14. In April, the short-seller compared Inovio to Theranos, the fraudulent blood testing company that has since dissolved.
Coronavirus cases are increasing in large swaths of the U.S. and Brazil, which together account for more than 3 million cases of Covid-19.
Vaccine Maker Inovio Jumps as Short-Seller Citron Bashes Company
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.